Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outpatient biological treatment for psoriasis: etanercept vs adalimumab
2009-015099-86Phase 4Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of etanercept and adalimumab in psoriasis (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: PASI 50 response at 3 months. Started Aug 2009; status: terminated.
02
Drugs
etanerceptadalimumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2009-015099-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015099-86.